For the boyish-looking Shkreli … purchase in 2014 of rights to a life-saving drug that he promptly raised the price from $13.50 to $750 per pill. Several potential jurors were kept off the panel after expressing distain for the defendant, with one calling him a “snake” and another “the face of corporate greed.”
The brash Mr. Shkreli was convicted by a federal jury in Brooklyn.
Martin Shkreli, 34 …. bulldozing his way into Wall Street and the drug industry, raising the price of a lifesaving drug by 5,000 percent overnight, boasting that he would outwit prosecutors in his federal fraud case, and live-streaming and tweeting throughout his five-week trial.
But on Friday, after five days of deliberations, jurors convicted him on three counts of fraud in federal court, and he now faces up to 20 years in prison on each of the first two counts, and up to five years on the final count.
Mr. Shkreli looked shaken as the judge read the verdict. But not long after, he appeared outside of court and returned to form, saying that he was “delighted, in many ways,” with the verdict. “This was a witch hunt of epic proportions, and maybe they found one or two broomsticks,” he said.
Later in the afternoon, he was live-streaming once more, sipping beer and joking about prison life from his Manhattan apartment.
A literal conspiracy across the FDA and state medical boards criminalizes natural medicine while pushing high-priced prescription drugs that cure nothing and only guarantee repeat business for the pharma drug cartels. The result is a massive, nationwide “wealth extraction” operation run by the drug companies…
To save America, we must declare independence from Big Pharma’s drug cartels
America spends almost one out of every four dollars of its GDP on “sick care” services. This is largely money that’s spent on a broken health care system dominated by Big Pharma’s toxic drugs that simply don’t work to prevent sickness and disease. This disastrous drug cartel serves only to transfer wealth from the population to the pockets of drug company shareholders and CEOs, and if America is to financially survive, it must reject this failed system of unaffordable, toxic medicine.
The FDA’s federally-enforced drug monopoly must end, and we as a nation must legalize natural medicine for everyone, including protecting doctors and health practitioners who wish to prescribe natural medicine to their patients (but will currently lose their medical licenses if they attempt such things).
The primary enforcer of the toxic pharmaceutical cartels that are bankrupting America — the FDA — must be gutted from top to bottom. The agency serves as nothing but a drug-pushing protection racket enforcer, targeting natural medicine manufacturers for destruction while colluding with drug companies to keep dangerous, costly prescription medications widely available even when they are killing hundreds of thousands of Americans each year. Thanks to the FDA, for example, prescription opioid deaths have now surpassed all gun-related deaths in America
JUL 23 by J HERMAN
According to the CDC, prescription medications put consumers at a much greater risk than illegal drugs. They estimate the death toll related to pharmaceutical drugs at 23,000 for the year 2013 alone. That puts prescription drugs such as oxycontin and tricyclic antidepressants at a much higher likelihood for causing death than drugs commonly seen as ‘killers’ such as heroin and cocaine.
So why are these prescription drugs not illegal? Well, thanks to massive advertising campaigns and the availability of information regarding the benefits but not the risks, many people don’t see prescription medications as quite on the same page as illicit substances.
And then there’s the honest fact that there is far much more money and power involved in funding drug wars while shoving toxic poison with minimal benefits down the throats of everyone from teenagers to senior citizens.
How can we solve this issue? The same CDC report that broke the statistics suggests that campaigns must be put together that inform both adults and children about the risks associated with prescription drugs and the likelihood of abuse, which stands much higher than many people believe.
But it’ll be hard to make that happen while our government is still fully supporting the interests of large pharmaceutical companies around the world and launching misleading campaigns against a drug trade who’s products kill less people than their so-called cures.
Diseases of the brain are rampant in America today, and evidence suggests that a popular class of pharmaceutical drugs may be largely to blame. They’re known as statins, and the science behind how they function in the body reveals that these powerful drugs gradually degrade the brain by depriving it of cholesterol, leading to memory problems, dementia and other similar conditions.
In his book Lipitor: Thief of Memory, Dr. Duanne Graveline, M.D., wrote about his horrific experience with statins, and how they caused him to suffer two transient global amnesia events as well as chronic neuropathy. The former astronaut and aerospace medical research scientist explains how these traumatic events were the direct result of statins altering his brain.
Learn more: http://www.naturalnews.com/048213_statin_drugs_brain_function_memory_problems.html#ixzz3O82q3aI1
Wednesday, Jan 08, 2014
TOKYO – Japan’s health ministry plans to file a criminal complaint against the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug.Novartis Pharma KK has been under fire since a university said the data in clinical studies might have been skewed to promote Valsartan.
A ministry panel of experts concluded in September that Novartis Pharma KK should be held responsible for studies at various universities that used manipulated data on the drug.
The firm used data from the studies to market its drug, playing up its supposed additional benefits.
Tokyo’s Jikei University School of Medicine has retracted research that appeared in respected medical journal The Lancet six years ago due to data fabrication.
Kyoto Prefectural University of Medicine also concluded that its studies on the drug used incomplete clinical data.
Chiba University said in December it could not find intentional data fabrication but researchers failed to disclose 91 million yen ($880,000) in scholarship donations from the pharmaceutical company in the three years from 2007 to 2009.
Read more: http://yourhealth.asiaone.com/content/japan-file-criminal-complaint-against-novartis
AbbVie (recently split off from Abbott Laboratories), maker of Humira, and InterMune, maker of Esbriet, have filed a lawsuit against the European Medicines Agency (the European equivalent of the FDA) to block access to clinical trial data on the benefits and harms of their drugs, claiming that these vital facts are “trade secrets” whose release would harm their profits. Medical researches have been denied to clinical trial information.
Of course, when a drug causes cancer, release of clinical data information could potentially harm the profits of the company that makes it. Humira, a drug that is quickly becoming one of the best-selling drugs in the world causes cancer.
The FDA warning label on Humira warns of increased risk of “Lymphoma and other malignancies” including “a rare type of cancer called hepatosplenic T-cell lymphoma” that “often results in death,” along with “increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens.
In addition to Lymphoma, TB and other infections, Humira is also linked to the following:
- Skin Cancer
- Kaposi’s Sarcoma
- Histoplasmosis Cryptosporidium
All of which can lead to death.
Read more: http://www.collective-evolution.com/2013/09/04/major-pharmaceutical-company-wants-to-block-access-to-clinical-trial-data-of-their-drugs-in-fear-of-profit-loss/#_
A senior executive with Britain’s biggest drugs company has admitted that most prescription medicines do not work on most people who take them.
Allen Roses, worldwide vice-president of genetics at GlaxoSmithKline (GSK), said fewer than half of the patients prescribed some of the most expensive drugs actually derived any benefit from them.
It is an open secret within the drugs industry that most of its products are ineffective in most patients but this is the first time that such a senior drugs boss has gone public.
“The vast majority of drugs – more than 90 per cent – only work in 30 or 50 per cent of the people,” Dr Roses said. “I wouldn’t say that most drugs don’t work. I would say that most drugs work in 30 to 50 per cent of people. Drugs out there on the market work, but they don’t work in everybody.”
Some industry analysts said Dr Roses’s comments were reminiscent of the 1991 gaffe by Gerald Ratner, the jewellery boss, who famously said that his high street shops are successful because they sold “total crap”. But others believe Dr Roses deserves credit for being honest about a little-publicised fact known to the drugs industry for many years.
Dr Roses said doctors treating patients routinely applied the trial-and-error approach which says that if one drug does not work there is always another one. “I think everybody has it in their experience that multiple drugs have been used for their headache or multiple drugs have been used for their backache or whatever.
“It’s in their experience, but they don’t quite understand why. The reason why is because they have different susceptibilities to the effect of that drug and that’s genetic,” he said.
“Neither those who pay for medical care nor patients want drugs to be prescribed that do not benefit the recipient. Pharmacogenetics has the promise of removing much of the uncertainty.”
Therapeutic area: drug efficacy rate in per cent
- Alzheimer’s: 30
- Analgesics (Cox-2): 80
- Asthma: 60
- Cardiac Arrythmias: 60
- Depression (SSRI): 62
- Diabetes: 57
- Hepatits C (HCV): 47
- Incontinence: 40
- Migraine (acute): 52
- Migraine (prophylaxis)50
- Rheumatoid arthritis50
- Schizophrenia: 60
Read more: http://www.independent.co.uk/news/science/glaxo-chief-our-drugs-do-not-work-on-most-patients-575942.html